Medical treatment of idiopathic heavy menstrual bleeding. What is new? An evidence based approach
This review examines current and new medical treatments for idiopathic heavy menstrual bleeding, identifying the levonorgestrel-releasing IUD as most effective and noting emerging evidence for modified-release tranexamic acid, new contraceptive pills, and a contraceptive ring.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This evidence-based review examined current and newly introduced medical treatments for idiopathic heavy menstrual bleeding in reproductive-age women, synthesizing results from trials, reviews, and guidelines identified via PubMed to support a practical treatment algorithm. The review found that the levonorgestrel-releasing intrauterine system was the most effective long-term medical therapy, while emerging options with growing evidence included modified-release tranexamic acid, a new four-phasic estradiol valerate/dienogest contraceptive pill, and a contraceptive vaginal ring, along with limited experience using vaginal danazol. The key caveat explicitly noted is that treatment selection is framed for idiopathic heavy menstrual bleeding, implying that evidence may not directly apply to heavy bleeding from specific causes beyond the idiopathic category. Relevance to endometriosis: abnormal uterine bleeding is part of the broader differential evaluated in endometrial-pathology contexts discussed in adjacent cited material, though this paper’s main focus is medical management of idiopathic heavy menstrual bleeding rather than endometriosis itself.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Full text
16,392 characters
· extracted from
oa-doi-fallback
· 5 sections
· click to expand
Abstract
Methods
Results
Conclusion
References
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (67)
- Antifibrinolytics for heavy menstrual bleeding via openalex
- Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel via openalex
- Danazol for heavy menstrual bleeding via openalex
- Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial via openalex
- Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest via openalex
- Effective Treatment of Heavy Menstrual Bleeding With Estradiol Valerate and Dienogest via openalex
- Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): A Phase III trial via openalex
- Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age via openalex
- Estradiol valerate and dienogest: a new approach to oral contraception via openalex
- Estradiol Valerate and Dienogest: A Novel Four-Phasic Oral Contraceptive Pill Effective for Pregnancy Prevention and Treatment of Heavy Menstrual Bleeding via openalex
- Estradiol Valerate/Dienogest: A Novel Combined Oral Contraceptive via openalex
- Estradiol Valerate/Dienogest: A Novel Oral Contraceptive via openalex
- Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest via openalex
- Hemostatic Effects of a Novel Estradiol-Based Oral Contraceptive via openalex
- Medical Therapies for Chronic Menorrhagia via openalex
- Molecular and Cellular Causes of Abnormal Uterine Bleeding of Endometrial Origin via openalex
- Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest via openalex
- Randomized Trial of 2 Hormonal and 2 Prostaglandin‐inhibiting Agents in Women with a Complaint of Menorrhagia via openalex
- The FIGO systems for nomenclature and classification of causes of abnormal uterine bleeding in the reproductive years: who needs them? via openalex
- Why women consult with increased vaginal bleeding: a case-control study. via openalex
- doi:10.1016/s0029-7844(01)01555-1 via openalex
- doi:10.1016/s0015-0282(01)01689-2 via openalex
- doi:10.1016/j.contraception.2010.06.011 via openalex
- doi:10.1002/14651858.cd001016.pub2 via openalex
- doi:10.1093/humrep/deh604 via openalex
- doi:10.3109/13625189809167250 via openalex
- doi:10.1097/aog.0b013e3181a1d3ce via openalex
- doi:10.1186/1472-6874-11-26 via openalex
- doi:10.1016/s1701-2163(16)34151-2 via openalex
- doi:10.1016/j.contraception.2011.07.012 via openalex
- doi:10.1093/humrep/del478 via openalex
- doi:10.1080/01443610600913932 via openalex
- doi:10.1111/j.1365-2516.2007.01586.x via openalex
- doi:10.1002/14651858.cd000249.pub2 via openalex
- doi:10.1097/aog.0b013e3181f80a37 via openalex
- doi:10.1002/14651858.cd000154.pub2 via openalex
- doi:10.1016/j.fertnstert.2004.01.025 via openalex
- doi:10.1111/j.1471-0528.2005.00642.x via openalex
- doi:10.1097/aog.0b013e3181f20177 via openalex
- doi:10.1111/j.1471-0528.2004.00012.x via openalex
- doi:10.1016/j.contraception.2011.12.005 via openalex
- doi:10.1055/s-0031-1287662 via openalex
- doi:10.1016/j.contraception.2006.03.022 via openalex
- doi:10.1517/14656566.2011.598857 via openalex
- doi:10.2217/whe.11.9 via openalex
- doi:10.1002/14651858.cd003552.pub3 via openalex
- doi:10.1016/j.ajog.2003.11.016 via openalex
- doi:10.1097/aog.0b013e318212b333 via openalex
- doi:10.1159/000320336 via openalex
- doi:10.1002/14651858.cd000154 via openalex
- doi:10.1016/j.ajog.2011.05.015 via openalex
- doi:10.1136/bmj.c3771 via openalex
- doi:10.1002/14651858.cd003552.pub4 via openalex
- doi:10.1097/aog.0b013e3181ec622b via openalex
- doi:10.1111/j.1471-0528.1998.tb10172.x via openalex
- doi:10.1097/mjt.0b013e318205427a via openalex
- doi:10.1016/j.ajog.2011.05.016 via openalex
- doi:10.1016/j.contraception.2007.01.013 via openalex
- W1932709689 via openalex
- doi:10.1111/j.1479-828x.1990.tb02028.x via openalex
- doi:10.1007/s00404-011-1902-1 via openalex
- doi:10.1016/j.fertnstert.2008.04.023 via openalex
- doi:10.1016/0029-7844(95)00062-v via openalex
- doi:10.1111/j.1600-0412.2012.01361.x via openalex
- doi:10.2165/11598960-000000000-00000 via openalex
- doi:10.1016/j.mce.2006.03.025 via openalex
- doi:10.3109/00016346609158455 via openalex
Cited by (2)
Source provenance
- openalex
- last seen: 2026-05-14T06:08:44.784461+00:00